TransCode Therapeutics, Inc.
RNAZ
$0.38
-$0.02-5.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -5.92M | -2.32M | -5.19M | -3.33M | -4.09M |
| Total Depreciation and Amortization | 122.90K | 127.50K | 142.80K | 141.60K | 140.20K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.70M | 204.50K | 1.14M | 183.20K | 310.30K |
| Change in Net Operating Assets | 942.30K | -1.92M | 1.56M | -935.20K | -2.03M |
| Cash from Operations | -3.15M | -3.91M | -2.34M | -3.94M | -5.66M |
| Capital Expenditure | -500.00 | -12.90K | -4.60K | -3.80K | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -500.00 | -12.90K | -4.60K | -3.80K | 0.00 |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 7.08M | 2.45M | 785.20K | 6.09M | 978.20K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 7.08M | 2.45M | 785.20K | 6.09M | 978.20K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.94M | -1.48M | -1.56M | 2.15M | -4.69M |